Supplementary Materials

Supplementary Material for:

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Timothy P. Sheahan, Amy C. Sims, Rachel L. Graham, Vineet D. Menachery, Lisa E. Gralinski, James B. Case, Sarah R. Leist, Krzysztof Pyrc, Joy Y. Feng, Iva Trantcheva, Roy Bannister, Yeojin Park, Darius Babusis, Michael O. Clarke, Richard L. Mackman, Jamie E. Spahn, Christopher A. Palmiotti, Dustin Siegel, Adrian S. Ray, Tomas Cihlar, Robert Jordan, Mark R. Denison,* Ralph S. Baric*

*Corresponding author. Email: mark.denison{at} (M.R.D.); rbaric{at} (R.S.B.)

Published 28 June 2017, Sci. Transl. Med. 9, eaal3653 (2017)
DOI: 10.1126/scitranslmed.aal3653

This PDF file includes:

  • Materials and Methods
  • Fig. S1. In vitro toxicity and efficacy of GS-5734 in 2B4 cells.
  • Fig. S2. In vitro toxicity of GS-5734 in primary HAE cell cultures.
  • Fig. S3. In vitro toxicity of GS-5734 in primary NHBE cell cultures.
  • Fig. S4. SARS-CoV in vivo pathogenesis is similar in WT and Ces1c−/− mice.
  • Fig. S5. Metabolism in NHBE cells and pharmacokinetic analysis in nonhuman primates.
  • Fig. S6. GS-5734 diminishes SARS-CoV–induced lung pathology.
  • Fig. S7. Therapeutic administration of GS-5734 beginning at 2 dpi does not provide a therapeutic benefit.
  • Fig. S8. A comprehensive platform approach to evaluate therapeutics against emerging viral infections.
  • Table S1. CoV genomic and subgenomic real-time primer sets.
  • Table S2. Primer/probe sets for indicators of cellular apoptosis/toxicity qRT-PCR.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S3 (Microsoft Excel format). Primary data.